Date Fruit Extract / TumCI Cancer Research Results

DFE, Date Fruit Extract: Click to Expand ⟱

Features:

Dates (the fruit of Phoenix dactylifera) have been increasingly studied for their potential anticancer and cancer-preventive properties, mainly due to their rich phytochemical content and strong antioxidant activity.
Dates contain a broad spectrum of bioactive compounds linked to cancer prevention:
-Phenolic acids – e.g., ferulic acid, gallic acid, caffeic acid, and p-coumaric acid
-Flavonoids – e.g., quercetin, luteolin, apigenin
-Carotenoids – e.g., β-carotene, lutein
-Tannins, saponins, and sterols
-Dietary fiber and polysaccharides
These compounds have antioxidant, anti-inflammatory, and antiproliferative effects.

Date fiber and polyphenols foster beneficial gut bacteria (e.g., Bifidobacterium, Lactobacillus) that produce short-chain fatty acids (SCFAs), which protect the colon and may lower colon cancer risk.

Date Fruit Extract — a non-standardized botanical extract prepared from the edible fruit pulp of Phoenix dactylifera L., including cultivars such as Ajwa, Medjool, Hallawi, Sukkari, and others. It is classified as a complex food-derived phytochemical mixture rather than a single defined drug or active pharmaceutical ingredient. The standard abbreviation is DFE. Principal constituents vary substantially with cultivar, ripeness, processing, and extraction solvent, but commonly include phenolic acids such as gallic, ferulic, caffeic, protocatechuic, and p-coumaric acids; flavonoids such as quercetin, luteolin, apigenin, catechin, and epicatechin derivatives; carotenoids; condensed tannins; polysaccharides; and dietary fiber. Date fruit, date seed, leaf, pollen, and nanoparticle preparations are compositionally distinct and should not be treated as interchangeable with fruit-pulp extract.

Primary mechanisms (ranked):

Induction of mitochondrial apoptosis in susceptible cancer cells, involving mitochondrial membrane depolarization, BAX/BCL-2 imbalance, caspase activation, and DNA fragmentation.
Suppression of cancer-cell proliferation through cell-cycle arrest, with reported accumulation in G1 or G2/M phases depending on the extract, concentration, and tumor model.
Redox modulation, including antioxidant protection in normal tissues but concentration-dependent ROS and mitochondrial ROS elevation in some cancer-cell models.
Modulation of p53-associated stress and apoptotic signaling in responsive tumor cells.
Anti-inflammatory activity through suppression of NF-κB-associated inflammatory signaling and inflammatory mediators, although direct tumor-specific evidence is limited.
Secondary modulation of PI3K/AKT and related survival signaling, reported inconsistently and not established as a universal mechanism.
Potential suppression of migration, clonogenic survival, angiogenic signaling, and tumor growth in selected preclinical models.
Indirect colon-health effects through fermentable fiber and polyphenol interactions with the gut microbiota and production of short-chain fatty acids.

Bioavailability / PK relevance: No clinically validated pharmacokinetic profile exists for DFE as a standardized anticancer agent. Its polyphenols undergo incomplete intestinal absorption, extensive phase-II conjugation, microbial metabolism, and rapid systemic clearance. Consequently, circulating concentrations of individual parent compounds are generally much lower than concentrations used for direct cancer-cell cytotoxicity. Local gastrointestinal exposure and microbial metabolites may be more biologically relevant than systemic exposure after ordinary date consumption.

In-vitro vs systemic exposure relevance: Most antiproliferative studies use crude solvent fractions at tens to hundreds of micrograms per millilitre. These concentrations cannot be directly equated with plasma exposure after eating dates or taking an unstandardized extract. Extract-specific cytotoxic effects may reflect concentrated mixtures, solvent-selective enrichment, or interactions among multiple constituents. Common in-vitro exposures probably exceed achievable systemic concentrations from dietary intake.

Clinical evidence status: Preclinical. Evidence consists primarily of cell-culture studies, limited animal experiments, compositional studies, and small human dietary studies evaluating metabolic, inflammatory, or gastrointestinal outcomes. No randomized controlled oncology trial has established DFE as a cancer treatment, adjunctive anticancer therapy, radiosensitizer, or chemotherapy sensitizer. Date fruit and date-derived extracts are not approved by Health Canada, the FDA, or the EMA as anticancer drugs.

Safety and deployment: Whole dates are conventional foods and are generally well tolerated, but they contain substantial carbohydrate and sugar and may require portion control in people with impaired glycemic regulation. Extracts may differ markedly from the food in concentration, solvent residues, composition, and contaminant risk. Clinical interaction data with chemotherapy, anticoagulants, endocrine therapies, or targeted agents are inadequate. DFE should not be assumed to protect normal tissue selectively or improve anticancer treatment efficacy without direct combination studies.

Date Fruit Extract Mechanistic Profile

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Mitochondrial apoptosis	MMP ↓; BAX ↑; BCL-2 ↓; caspase-3 ↑; apoptosis ↑	Apoptotic injury often ↓ in oxidative-damage models	R, G	Programmed cancer-cell death	Best-supported direct anticancer mechanism, but demonstrated mainly with concentrated Ajwa or solvent-fraction extracts in vitro.
2	Cell-cycle control	Proliferation ↓; G1 or G2/M arrest ↑ (model-dependent)	↔	G	Cytostasis	Cell-cycle phase varies by tumor line, cultivar, solvent fraction, concentration, and exposure duration.
3	ROS and mitochondrial oxidative stress	ROS ↑; mitochondrial ROS ↑ (dose-dependent)	ROS ↓; lipid peroxidation ↓; antioxidant capacity ↑	P, R	Context-dependent redox modulation	Cancer-cell pro-oxidant activity has been reported, while antioxidant protection predominates in normal-tissue injury models. Tumor selectivity is not clinically established.
4	p53 stress response	p53 ↑; apoptotic signaling ↑ (model-dependent)	↔	R, G	Stress-mediated growth suppression	Reported in selected models and should not be generalized to p53-deficient or mutant-p53 tumors.
5	NF-κB inflammatory signaling	NF-κB-associated survival and inflammation ↓ (limited evidence)	Inflammatory signaling ↓	R, G	Anti-inflammatory modulation	More consistently supported in inflammatory or tissue-injury systems than in direct oncology experiments.
6	PI3K and AKT survival signaling	PI3K/AKT ↓ (context-dependent)	↔ or AKT support ↑ in injury models	R, G	Survival-pathway suppression	Not consistently measured across DFE studies and may partly reflect activities of individual phenolic constituents.
7	Clonogenic survival and tumor growth	Colony formation ↓; tumor-cell burden ↓ in limited models	↔	G	Long-term growth inhibition	Evidence is substantially weaker than for established anticancer agents and remains extract-specific.
8	Migration and invasion	Migration ↓; invasion-related signaling possibly ↓	↔	G	Potential antimetastatic activity	Limited mechanistic data; MMP and epithelial-mesenchymal transition effects require further confirmation.
9	Angiogenic signaling	VEGF-associated signaling possibly ↓	↔	G	Potential angiogenesis suppression	Sparse evidence and not established as a primary effect of fruit-pulp extract.
10	NRF2 antioxidant response	NRF2 modulation mixed (context-dependent)	NRF2 and antioxidant enzymes ↑	R, G	Secondary cytoprotective response	NRF2 activation may protect normal tissues but could theoretically support antioxidant resistance in some cancers. Direct DFE tumor data are insufficient to define the net effect.
11	Gut microbiota and short-chain fatty acids	Indirect colon-environment modulation	Beneficial bacterial growth ↑; fermentation products ↑	G	Local gastrointestinal and metabolic effect	Human dietary evidence supports microbiota and bowel-environment effects more strongly than systemic anticancer activity.
12	Clinical Translation Constraint	Effective exposure uncertain; extract composition heterogeneous	Food-level tolerance generally favorable	G	Limits clinical interpretation	Major constraints include cultivar and solvent variability, absent extract standardization, low systemic polyphenol exposure, high in-vitro concentrations, limited animal oncology evidence, and no controlled cancer trials.

TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr

TumCI, Tumor Cell invasion: Click to Expand ⟱

Source:

Type:

Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.

Scientific Papers found: Click to Expand⟱

6664-

DFE,

Anticancer Properties of Different Varieties of Date Palm (Phoenix dactylifera L.) Leaf Extracts in Human Tumor Cells: a Comparative Study

in-vitro,

BC,

MDA-MB-231

in-vitro,

GBM,

U87MG

TumCG↓, TumCMig↓, TumCI↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,

Migration(tgid=13) ⓘ

TumCI↓, 1, TumCMig↓, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells